Comparative Pharmacology
Head-to-head clinical analysis: LOESTRIN 24 FE versus LOESTRIN FE 1 5 30.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LOESTRIN 24 FE versus LOESTRIN FE 1 5 30.
LOESTRIN 24 FE vs LOESTRIN FE 1.5/30
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination estrogen-progestin contraceptive. Suppresses gonadotropin (FSH, LH) release via negative feedback, inhibiting ovulation. Increases cervical mucus viscosity, reducing sperm penetration. Alters endometrial development, decreasing implantation likelihood.
Suppresses gonadotropin (FSH and LH) release via estrogen and progestin feedback inhibition, preventing ovulation; increases cervical mucus viscosity and alters endometrial lining.
One tablet (1 mg norethindrone acetate/20 mcg ethinyl estradiol) orally once daily for 24 days, followed by a low-dose iron-containing tablet (75 mg ferrous fumarate) for 4 days.
One tablet orally once daily at the same time each day for 21 consecutive days, followed by 7 days of placebo (ferrous fumarate) tablets, then restart.
None Documented
None Documented
Norethindrone: 5-12 hours; Ethinyl estradiol: 13-27 hours. The terminal half-life supports once-daily dosing; steady state is achieved within 5-7 days.
Norethindrone: ~5-14 hours (terminal); Ethinyl estradiol: ~13-27 hours (terminal). Clinically, steady-state achieved within 5-7 days.
Ethinyl estradiol and norethindrone are primarily excreted in urine (about 50-60%) and feces (about 30-40%) as glucuronide and sulfate conjugates after hepatic metabolism.
Renal: ~50-60% (norethindrone metabolites); Fecal: ~20-30% (norethindrone); Ethinyl estradiol: primarily renal (~40-50%) and fecal (~20-50%) as glucuronide and sulfate conjugates.
Category C
Category C
Combined Oral Contraceptive
Combined Oral Contraceptive